

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

Reference is made to the announcements of the Company dated January 26, 2024, January 29, 2024, February 4, 2024 and February 13, 2024, in relation to, among other things, WuXi AppTec being named in certain proposed legislation that was recently introduced in the U.S. House of Representatives and the U.S. Senate.

The Company has learned that on March 6, 2024 the U.S. Senate Committee on Homeland Security and Government Affairs (the “**Senate Committee**”) voted to report to the Senate a revised draft bill S.3558 (“**Bill S.3558**”). The revised draft bill incorporates certain amendments including, among others, a “grandfather” clause that exempts existing contracts entered into before the effectiveness of the proposed legislation and a process for U.S. government agencies to designate and review companies of concern. Despite such amendments and existing processes at U.S. government agencies for evaluating national security concerns, Bill S.3558 would preemptively designate WuXi AppTec by including its name within the definition of a “biotechnology company of concern”. The Company strongly disagrees with such preemptive and unfair designation without due process, and we firmly believe that WuXi AppTec has not posed, does not pose, and will not pose a security risk to the United States or any other country. We also reiterate that WuXi AppTec does not have a human genomics business or collect human genomic data.

Bill S.3558 will continue to go through the legislative process in the Senate in the coming months. The Company will work closely with its advisors to continue our engagement and dialogue with the relevant stakeholders involved in the ongoing legislative process for Bill S.3558 and a corresponding bill in the U.S. House of Representatives, the contents of which remain subject to further review and changes.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, March 7, 2024

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* *For identification purposes only*